Gesamter Bestand

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease

Thumbnail
Autor
Katsiki N., Tentolouris N., Marakomichelakis G., Richter D., Giannoukas A., Koufaki P., Papanas N., Alexopoulos I., Anastasiadis F., Andreadis E., Andreopoulos G., Apostolidis D., Christodoulou I., Christopoulos I., Dalaberis E., Daliani H., Dimitriou G., Dimitsikoglou I., Dimoulis N., Doulgerakis D., Douloumpakas I., Drakopoulou E., Felekis T., Feloukas T., Florou S., Fragakis D., Fregidis T., Gakis P., Galanakis C., Giakoumis A., Giannes N., Galapis A., Gouveris I., Groutsis T., Grapsas V., Grigoropoulos P., Iordanidis T., Kazakos K., Kazantzi M., Kapernopoulos H., Kapetanios K., Karagianni E., Karakostas F., Karapiperis D., Karotsis A., Karsanidis A., Kasfikis F., Kourouklis S., Kourtis T., Kourtidou P., Koutsias S., Kotsogiannis S., Lampousakis I., Latsios P., Liouri I., Makrygiannis P., Matsouki W., Bakalakou K., Bakiris P., Balogianni M., Benis A., Beri V., Beroukas A., Moysidis K., Nanos E., Nikolaou A., Dubovina M., Oikonomidis N., Pangalos E., Panagoulias G., Papadopoulos S., Paraskevas G., Peroulis M., Petoumenos V., Petrogiannis S., Pournaras G., Pourou H., Prionidis M., Rigas A., Rigas S., Rigopoulos D., Sakellariou D., Sarafianos P., Svolis K., Seferou M., Sklirou V., Spais G., Stathopoulos C., Stavridou V., Stavrou I., Sfiniadakis I., Tatola V., Topalidis I., Trikkalinou A., Tsagarakis D., Tsarouchas P., Valkaniotis G., Varella M., Vasilakakou S., Vlachopoulou M., Vouzas A., Zafeiriou I., Zafeiris I., Zacharopoulou O., Zinelis D., CI-WIN Investigators
Datum
2022
Language
en
DOI
Schlagwort
Zur Langanzeige
Zusammenfassung
Objective: to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study. We included 1015 PAD patients presenting with IC (71.3% men, 93.5% white, mean age 69.2 ± 8.7 years). Patients were followed up for 6 months by their physicians. Results: Cilostazol significantly increased pain-free walking distance by a median of 285 and 387 m at 3 and 6 months, respectively (p < 0.01 for all comparisons). This effect was significant for patients 50–74 years (but not for those aged ≥ 75 years) and independent of smoking status, changes in physical activity, comorbidities and concomitant medication for PAD (i.e., acetylsalicylic acid and clopidogrel). Furthermore, significant reductions were observed in systolic (from 139 ± 16 to 133 ± 14 mmHg; p < 0.001) and diastolic blood pressure (from 84 ± 9 mmHg to 80 ± 10 mmHg; p < 0.001). Smoking cessation and increased physical activity were reported by the majority of participants. In conclusion, cilostazol was shown to safely decrease pain symptoms and improve pain-free walking in PAD patients with IC in a real world setting. Benefits also occurred in terms of BP and lifestyle changes. © 2022, The Author(s).
URI
http://hdl.handle.net/11615/74640
Collections